Antibiotic Regulatory Genes and Metabolic Engineering

Information

  • Research Project
  • 6405650
  • ApplicationId
    6405650
  • Core Project Number
    R44GM058943
  • Full Project Number
    2R44GM058943-02A1
  • Serial Number
    58943
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/15/1999 - 25 years ago
  • Project End Date
    8/31/2003 - 21 years ago
  • Program Officer Name
    JONES, WARREN
  • Budget Start Date
    9/1/2001 - 23 years ago
  • Budget End Date
    8/31/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    2
  • Suffix
    A1
  • Award Notice Date
    8/19/2002 - 22 years ago
Organizations

Antibiotic Regulatory Genes and Metabolic Engineering

DESCRIPTION (provided by applicant): Strain improvement of commercial fermentations helps to reduce the cost of production of existing pharmaceuticals and helps industry to meet the growing demands for desperately needed new products, such as antibiotics, that can be produced in large enough quantities and at prices the public can afford. This project focuses on strain improvement in a bacterium that generates a widely used antibiotic, erythromycin. This bacterium, Saccharopolyspora erythraea, is a member of the Actinomycete family and is widely used in academic research and industry, making it an excellent model system for this work. The objective of this project is to identify and manipulate genes responsible for controlling erythromycin yield during fermentation. In Phase I a mutagenic plasmid insertion library was created in Sac. erythraea and four classes of morphological and pigmentation mutants were found using a simple visual screen. Three classes of mutants were found that showed significant increases in erythromycin production. An efficient plasmid rescue technique allowed recovery of the integrated plasmid and DNA sequence analysis of the plasmid insert. In Phase II the screening and mutant analysis will continue. The strain improvement genes found could have general application to strain improvement programs for other drugs. PROPOSED COMMERCIAL APPLICATION: Not Available

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    334900
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:334900\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    FERMALOGIC, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CHICAGO
  • Organization State
    IL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    60612
  • Organization District
    UNITED STATES